At present, Non-Communicable diseases (NCDs) have become important issues of public health in Thailand, according to the WHO found that the NCDs have become a major cause of death over 60 percent of all causes. They compose of death from heart disease, Stroke, diabetes, cancers and chronic respiratory diseases. The data showed that the incidences of this disease in Thailand are increasing exponentially every year. If no control measures to reduce the risk of diseases, this problem is becoming increasingly severe. This will affect the quality of life of the population and the economy of the country.

In order to reduce the incidence of NCDs in general, it there is a great need to start on a personal level. Therefore, it is important to understand Thais’ perception in personal health care and risk factors that could affect spur these diseases. After we understand people’s behaviors, it could be used to develop effective measures to prevent NCDs them. It is estimated that more than 50 percent of the rate of death and disability due to NCDs are preventable. Such numbers call for a broad collaboration between Therefore considered a common good that the pharmaceutical industry, civil society and government agencies to participate in the on activity for the disease prevention programs to help eliminate and address the risk factors that lead to the diseases. The end result will not only be limited to the better health of Thai people but it will also lead to a reduction in the budget for the treatment of NCDs care in the future.

Neglected Tropical Disease: NTDs

Health is wealth. Nowhere is this more poignantly evident than in areas where NTDs are present and impede economic development. Taking steps to reduce the toll of NTDs takes long-term and wide-ranging commitment from governments, civil society and business. The research-based biopharmaceutical industry has stepped up to the plate, not only with historic levels of drug donations, but also with long-term commitment to R&D. The 100-plus active research projects for NTDs, and growing year-on-year research funding in this area, are boosting innovation to combat NTDs.

How is pharma contributing to the global fight against NTDs?
  • The industry was among original signatories to the London Declaration, pledging support to control or eliminate the ten NTDs responsible for more than 90% of the global NTD burden by 2020. IFPMA is presenting its progress report to stakeholders at the WHO NTD Summit, 19-22 April 2017.
  • The industry contributes to the WHO Roadmap on NTDs through a wide range of activities: through R&D of new treatments, donation of existing treatments, and capacity building.
  • The industry is delivering on its promise of 14 billion donated treatments ($17.8bn of drug donations) over 10 years. In 2015 alone, an estimated 1.5 billion treatments have been distributed (that’s around 50 treatments every second!).
  • IFPMA companies are also engaged in over 40 partnerships to strengthen health system capacities and improve public awareness on disease prevention - see IFPMA Health Partnerships Directory.



What do the results of the NTD R&D report show?
  • There has been considerable progress in new technologies, including medicines, vaccines, diagnostics and pesticides, to combat NTDs. The industry is engaged in 109 active R&D projects for NTDs.
  • There have been recent breakthroughs in Dengue, Soil-transmitted helminthiases and Lymphatic filariasis. Nearing the end of what is on average a 10-15 year R&D process, IFPMA member companies and their partners are approaching additional imminent breakthroughs in American Trypanosomiasis (Chagas), dengue, Human African trypanosomiasis (sleeping sickness), lymphatic filariasis, rabies, and trachoma.
  • To ensure that new generations of improved treatments and interventions are discovered, despite low commercial incentives in the area of NTDs, the industry engages in a variety of innovative research models, such as PDPs. 90% of active programs are collaborative efforts with over 50 organizations.

How are industry commitments to R&D part of a holistic approach on global health?
  • G-FINDER 2016 shows the pharmaceutical industry is contributing USD 471 m to neglected disease R&D (NTDs as well as TB, HIV, malaria, Ebola, etc,), and is the only sector to have recorded year-on-year growth for the last four years (compared to public and philanthropic sectors).
  • The ATM Index has also shown that increasingly, the R&D investments made by innovative biopharmaceutical companies is linked to programs that ensure patients receive the treatments as soon as is possible and are affordable.
  • Towards wider efforts to control the spread of emerging infectious diseases, the industry has recently contributed to combatting AMR (Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance, Jan 2016) and defending against future pandemics (Coalition for Epidemic Preparedness Innovations (CEPI), Jan 2017).

Health article & Infographic